Long-Term Efficacy and Safety of Sodium Channel Antagonists in Patients With p.R222Q SCN5A-Related Arrhythmic Dilated Cardiomyopathy
Authors:
- Stacey PetersSPStacey Peters
- Renee JohnsonRJRenee Johnson
- Dominica ZentnerDZDominica Zentner
- Paul JamesPJPaul James
- Jonathan M. KalmanJKJonathan M. Kalman
- Diane FatkinDFDiane Fatkin
- 1 January 2021
- journal article
- letter
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 7 (1) , 126-128
Abstract
No abstract availableFunding Information
- National Health and Medical Research Council
- NSW Health
- Victor Chang Cardiac Research Institute
- Melbourne Institute, University of Melbourne
This publication has 5 references indexed in Scilit:
- Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case reportBMC Medical Genetics, 2018
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- R222Q SCN5A Mutation Is Associated With Reversible Ventricular Ectopy and Dilated CardiomyopathyJACC, 2012
- Escape capture bigeminy: Phenotypic marker of cardiac sodium channel voltage sensor mutation R222QHeart Rhythm, 2012
- Multifocal Ectopic Purkinje-Related Premature ContractionsJACC, 2012